Posted: 9 month(s) and 14 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

MDRNA (MRNA.NSDQ) shot up $1.16, or 75%, to $2.70 after the FDA approved the company's generic version of the osteoporosis treatment Miacalcin. The stock was the biggest gainer on the Nasdaq today.

MDRNA said U.S. sales of Miacalcin totaled $112 million in 2008. Novartis AG makes Miacalcin. MDRNA partners with Par Pharmaceuticals (PRX.NYSE) to make the generic Miacilin.

MDRNA shares had been languishing below $1 for most of 2009, so it will be interesting to see how the stock performs in light of today's news.

Member Rating: 0 0